| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000013542 |
| Receipt No. | R000015774 |
| Official scientific title of the study | Does Quetiapine improve mood symptoms in schizophrenia patients? |
| Date of disclosure of the study information | 2014/03/28 |
| Last modified on | 2016/06/19 (Ver. 4) |
| Basic information | ||
| Official scientific title of the study | Does Quetiapine improve mood symptoms in schizophrenia patients?
|
|
| Title of the study (Brief title) | Does Quetiapine improve mood symptoms in schizophrenia patients?
|
|
| Region |
|
|
| Condition | ||
| Condition | Schizophrenia | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To evaluate the effectiveness of quetiapine on schizophrenia patients with depressive symptoms |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | HAM-D17 |
| Key secondary outcomes | BPRS
DIEPSS Blood test |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1.Chronic schizophrenia patients with depressive symptoms who have started the treatment with quetiapine
2.Patients whose positive symptoms are stable enough to keep a long term treatment with quetiapine 3.Patients who do not receive antidepressants 4.Age 18 and over |
|||
| Key exclusion criteria | Cases judged inadequate by medical doctor | |||
| Target sample size | 30 | |||
| Research contact person | |
| Name of lead principal investigator | Setsuko Yasugawa |
| Organization | Yatsushiro Kosei Hospital |
| Division name | Departmennt of psychiatry |
| Address | Furushiromachi1705 Yatsushiro-shi Kumamoto |
| TEL | 0965-33-4025 |
| yasugawa@orange.ocn.ne.jp | |
| Public contact | |
| Name of contact person | Setsuko Yasugawa |
| Organization | Yatsushiro Kosei Hospital |
| Division name | Departmennt of psychiatry |
| Address | Furushiromachi1705 Yatsushiro-shi Kumamoto |
| TEL | 0965-33-4025 |
| Homepage URL | |
| yasugawa@orange.ocn.ne.jp | |
| Sponsor | |
| Institute | Yatsushiro Kosei Hospital |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | Astellas Pharma Inc. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 八代更生病院(熊本県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | Depressive symptoms in schizophrenia patients wil be described. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015774 |